FREE DOWNLOAD
The Protein-PCR™ Advantage
How AperionDx’s Protein-PCR is transforming the detection and monitoring of Traumatic Brain Injury (TBI) and Alzheimer’s Disease
Download our detailed checklist to evaluate the benefits of next-generation biomarker testing technology and see why it represents a breakthrough opportunity in neurological diagnostics.
FREE DOWNLOAD
The Protein-PCR™ Advantage
How AperionDx’s Protein-PCR is transforming the detection and monitoring of Traumatic Brain Injury (TBI) and Alzheimer’s Disease
Download our detailed checklist to evaluate the benefits of next-generation biomarker testing technology and see why it represents a breakthrough opportunity in neurological diagnostics.
"In the last 30 days, we’ve: validated Protein-PCR assay performance across multiple biomarkers, optimized protocols for TBI detection, confirmed reproducibility across independent lab sites, finalized regulatory pathway outlines, and engaged with early-stage clinical collaborators. The pace of progress has been both exciting and decisive."
Dr. Sarah M., Neuroscience Research Collaborator
IN THIS FREE CHECKLIST, YOU’LL DISCOVER:
IN THIS FREE CHECKLIST, YOU’LL DISCOVER:
TECHNOLOGY BENCHMARKS
See how Protein-PCR compares to traditional ELISA and immunoassays—faster detection, higher sensitivity, and multiplexing capabilities that reduce cost per test.
MARKET OPPORTUNITY
Understand the unmet need for rapid, reliable biomarker testing in neurological disease and the global demand for early detection and monitoring solutions.
SCALABILITY INSIGHTS
Learn how Protein-PCR is designed to scale from research labs into clinical diagnostic environments, addressing both current investigator needs and future patient care.
INVESTOR READINESS FACTORS
The essential markers that show Protein-PCR is not just scientifically sound, but also commercially viable.
18 commercialized products, including 12 FDA-approved.
2x recipient of Industrial Research 100 Awards for Best New Product of the Year in the United States.
Hi, I’m Bill Pagels — founder of AperionDx. For decades, I’ve worked at the forefront of biotech and diagnostics, helping bring breakthrough products from concept to market.
Our Protein-PCR Advantage Checklist captures the key elements that make this technology transformative — for scientists, clinicians, and investors alike.
Without it, opportunities to innovate in neurological testing could be delayed by outdated methods, slower timelines, and missed chances to impact patient care.
With it, you’ll clearly see how Protein-PCR is positioned to drive faster adoption, stronger results, and a new standard in biomarker testing.
So, let’s move science — and diagnostics — forward.
X Bill Pagels
WHAT RESEARCH PARTNERS ARE SAYING ABOUT APERIONDX…
"Protein-PCR provided us with biomarker sensitivity we simply could not achieve with ELISA. It opened a new window into early TBI detection."
Dr. R.K., Clinical Neurologist
"Reproducibility and scalability are what impressed me most. This is exactly the kind of platform that translates from lab to clinic."
Dr. A.J., Translational Scientist
"It’s rare to see a technology that combines technical rigor with commercial foresight. Protein-PCR is one of them."
Dr. T.L., Investor-Scientist